Back to search

Peptide record

TPDB03268

Hecate (Hec) Hecate Ac Antibacterial Anticancer Antifungal Antiparasitic Antiviral Cell-penetrating Peptides Hemolysis Toxicity standard
23 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB03268
Hecate (Hec) Hecate Ac
Antibacterial Anticancer Antifungal Antiparasitic Antiviral Cell-penetrating Peptides Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides Delivery and barrier-penetrating peptides
AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb iACP-DRLF pep-lab Antifungipept CAFPdb AI4AVP AVPpred-BWR dbAMP 3.0 DRAVP 2.0 CPPsite3.0 PD_Hemolysis
standard
No
A 23-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
FALALKALKKALKKLKKALKKAL
Physicochemical Analysis
C123H226N32O24
RNDCEQGHIMPSTWYV
K
2537.35
11.41
9
0
14
+9
2.84
0.222
144.78
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
0
0.00
0
Residue Composition
number
6
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
0
I
7
L
9
K
0
M
1
F
0
P
0
S
0
T
0
W
0
Y
0
V
Amino Acid Distribution
A: 6 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 0 L: 7 K: 9 M: 0 F: 1 P: 0 S: 0 T: 0 W: 0 Y: 0 V: 0
Chemical Descriptors
23
C123H226N32O24
2537.35
11.41
+9
2.84
0.222
Free
L
Amphipathic
Linear
Linear
Free
Anticancer
FLAK peptides
N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CS)C(=O)O
Evidence Records 13 records
Evidence 1 Activity

Activity

LD50
LD50 =54 µg/ml
Anticancer
54 µg/mL

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation. dbAMP 3.0 classified as Anticancer under the disease-associated peptide function classes.
Evidence 2 Activity

Activity

LD50
LD50 =6 µg/ml
Anticancer
6 µg/mL

Target

Colon Cancer
SW-480
Colon

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 3 Activity

Activity

LD50
LD50 =72 µg/ml
Anticancer
72 µg/mL

Target

Skin Cancer
BMKC
Skin

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 4 Activity

Activity

LD50
LD50 =44 µg/ml
Anticancer
44 µg/mL

Target

Lung Cancer
H-1299
Lung

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 5 Activity

Activity

LD50
LD50 =61 µg/ml
Anticancer
61 µg/mL

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 6 Activity

Activity

LD50
LD50 =95 µg/ml
Anticancer
95 µg/mL

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 7 Activity

Activity

Cell-penetrating Peptides

Target

Mrsa And Vrsa( Van-Resistant Enterococcus Faecalis)

Source & Reference

CPPsite3.0
CPPsite3

Other

Source Activity Label Source Definition
Cell-penetrating Peptides
CPPsite3.0 experimentally validated cell-penetrating peptide annotation.
Natural residues Linear L Amphipathic
Protein derived
Vancomycin (Van) via linker (CDI)
Van/Hec conjugate caused disruption of bacterial cell integrity in all the tested strains, which was not found in case of Van and Hec alone.
Membrane distruption
In vitro
CCSCCTTSSSCC
Evidence 8 Activity

Activity

LD50
Toxicity
27 µg/mL
Cytotoxic
LD50 | 27 | µg/mL | target cell: Human fibroblasts WI-38

Target

Human fibroblasts WI-38

Source & Reference

NA
DBAASP
Short bioactive peptides | PATENT US 6875744B2 | 2005
Evidence 9 Activity

Activity

50% Hemolysis
Toxicity
100 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 100 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Short bioactive peptides | PATENT US 6875744B2 | 2005
Evidence 10 Activity

Activity

50% Cytotoxicity
Toxicity
5.17 µM
Cytotoxic
50% Cytotoxicity | 5.17 | µM | target cell: Feline kidney epithelial CRFK cells

Target

Feline kidney epithelial CRFK cells

Source & Reference

NA
DBAASP
Inhibitory activity of synthetic peptide antibiotics on feline immunodeficiency virus infectivity in vitro. | J Virol | 2002
Evidence 11 Activity

Activity

LD50
Toxicity
66 µg/mL
Cytotoxic
LD50 | 66 | µg/mL | target cell: Human fibroblasts WI-38

Target

Human fibroblasts WI-38

Source & Reference

NA
DBAASP
Short bioactive peptides | PATENT US 6875744B2 | 2005
Evidence 12 Activity

Activity

50% Hemolysis
Toxicity
10 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 10 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Short bioactive peptides | PATENT US 6875744B2 | 2005
Evidence 13 Hemolysis

Source & Reference

PD_Hemolysis
PD_Hemolysis
Additional Detail Fields 1 fields
CCSCCTTSSSCC